1887

Abstract

The measurement of IgG anti-pertussis toxin (IgG anti-PT) antibodies by ELISA is a frequently used method for studying the antibody responses after pertussis vaccination and after infection. Such responses vary according to the different vaccines used as well as to the immunization and infection history of the participants. In the present study, the decay kinetics of the IgG anti-PT antibody response was determined for 71 Danish children and adults with bacteriologically confirmed infection and for 20 Danish adults booster-vaccinated with an acellular pertussis vaccine. For both groups, biphasic decay was seen, but the individual antibody responses varied greatly. No differences related to age were seen. Within each group, individual decay profiles showed parallel log-linear decay for the late part of the response. Antibody half-life was calculated for the late, slower part of the biphasic response curves for both groups (>5 months after diagnosis for individuals with confirmed infection; >3 months for vaccinated individuals). The median half-life for post-infection antibodies was 221 days [interquartile range (IQR) 159–314 days, 36 individuals], and the median half-life for post-vaccination antibodies was 508 days (IQR 428–616 days, 14 individuals). This difference was statistically significant (<0.0001). Thus, in this setting, we found that the IgG anti-PT antibody decay after an infection with is more than twice as fast as the decay after booster vaccination with an acellular pertussis vaccine. Such knowledge of the IgG anti-PT decay kinetics is crucial for interpretation of serological data that will be used either for diagnosis or for epidemiological studies and surveillance of infections.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.020826-0
2010-09-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/9/1029.html?itemId=/content/journal/jmm/10.1099/jmm.0.020826-0&mimeType=html&fmt=ahah

References

  1. Andersen, P. H., Valentiner-Branth, P., Glismann, S., Christiansen, A. H. & Simonsen, J. B. ( 2007; ). DTap-IPV/Hib vaccination: coverage by the end of 2005. EPI-NEWS No. 8, www.ssi.dk
    [Google Scholar]
  2. André, P., Caro, V., Njamkepo, E., Wendelboe, A. M., Van Rie, A. & Guiso, N. ( 2008; ). Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007. J Clin Microbiol 46, 1672–1677.[CrossRef]
    [Google Scholar]
  3. Bailleux, F., Coudeville, L., Kolenc-Saban, A., Bevilacqua, J., Barreto, L. & André, P. ( 2008; ). Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 26, 3903–3908.[CrossRef]
    [Google Scholar]
  4. Barreto, L., Guasparini, R., Meekison, W., Noya, F., Young, L. & Mills, E. ( 2007; ). Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 25, 8172–8179.[CrossRef]
    [Google Scholar]
  5. Baughman, A. L., Bisgard, K. M., Edwards, K. M., Guris, D., Decker, M. D., Holland, K., Meade, B. D. & Lynn, F. ( 2004; ). Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 11, 1045–1053.
    [Google Scholar]
  6. Bundesministerium für Gesundheit ( 2009; ). Evidenz-basierte Empfehlungen des Obersten Sanitätsrates. Impfplan 2009 Österreich. http://www.bmgfj.gv.at/..
  7. CDC ( 2010; ). Recommended adult immunization schedule – United States, 2010. MMWR 59, 1–4.
    [Google Scholar]
  8. Christensen, M. & Rønne, T. ( 1997; ). Coverage of the childhood vaccination programme 1988–1996. EPI-NYT Uge 47, www.ssi.dk (in Danish
    [Google Scholar]
  9. Dalby, T., Seier-Petersen, M., Kristiansen, M. P., Harboe, Z. B. & Krogfelt, K. A. ( 2009; ). Problem solved: a modified enzyme-linked immunosorbent assay for detection of human antibodies to pertussis toxin eliminates false-positive results occurring at analysis of heat-treated sera. Diagn Microbiol Infect Dis 63, 354–360.[CrossRef]
    [Google Scholar]
  10. de Melker, H. E., Versteegh, F. G. A., Conyn-van Spaendonck, M. A. E., Elvers, L. H., Berbers, G. A. M., van der Zee, A. & Schellekens, J. F. P. ( 2000; ). Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38, 800–806.
    [Google Scholar]
  11. Di Tommaso, A., Bartalini, M., Peppoloni, S., Podda, A., Rappuoli, R. & De Magistris, M. T. ( 1997; ). Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 15, 1218–1224.[CrossRef]
    [Google Scholar]
  12. Edelman, K., He, Q., Mäkinen, J., Sahlberg, A., Haanperä, M., Schuerman, L., Wolter, J. & Mertsola, J. ( 2007; ). Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 44, 1271–1277.[CrossRef]
    [Google Scholar]
  13. Edwards, K. M., Decker, M. D., Graham, B. S., Mezzatesta, J., Scott, J. & Hackell, J. ( 1993; ). Adult immunization with acellular pertussis vaccine. JAMA 269, 53–56.[CrossRef]
    [Google Scholar]
  14. Giammanco, A., Taormina, S., Genovese, M., Mangiaracina, G., Giammanco, G. & Chiarini, A. ( 1997; ). Serological responses to infection with B. pertussis. Dev Biol Stand 89, 213–220.
    [Google Scholar]
  15. Giuliano, M., Mastrantonio, P., Giammanco, A., Piscitelli, A., Salmaso, S. & Wassilak, S. G. F. ( 1998; ). Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 132, 983–988.[CrossRef]
    [Google Scholar]
  16. Hallander, H. O., Gustafsson, L., Ljungman, M. & Storsaeter, J. ( 2005; ). Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3½–6½ years after the third vaccine dose. Vaccine 23, 5359–5364.[CrossRef]
    [Google Scholar]
  17. Hallander, H. O., Ljungman, M., Storsaeter, J. & Gustafsson, L. ( 2009; ). Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS 117, 797–807.[CrossRef]
    [Google Scholar]
  18. Haut Conseil de la Santé Publique (2010). Calendrier vaccinal détaillé 2009. http://www.sante-jeunesse-sports.gouv.fr/.
  19. Heininger, U., Cherry, J. D. & Stehr, K. ( 2004; ). Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 38, 591–594.[CrossRef]
    [Google Scholar]
  20. Hendrikx, L. H., Berbers, G. A., Veenhoven, R. H., Sanders, E. A. M. & Buisman, A.-M. ( 2009; ). IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 27, 6530–6536.[CrossRef]
    [Google Scholar]
  21. Hodder, S. L., Cherry, J. D., Mortimer, E. A., Jr, Ford, A. B., Gornbein, J. & Papp, K. ( 2000; ). Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis 31, 7–14.[CrossRef]
    [Google Scholar]
  22. Isacson, J. ( 1997; ). Studies of pertussis epidemiology and of serum antibody responses to Bordetella pertussis antigens after disease and vaccination. Doctoral Thesis, Department of Pediatrics, SU/Östra sjukhuset, Göteborg University, Sweden.
  23. Keitel, W. A., Muenz, L. R., Decker, M. D., Englund, J. A., Mink, C. M., Blumberg, D. A. & Edwards, K. M. ( 1999; ). A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 180, 397–403.[CrossRef]
    [Google Scholar]
  24. Le, T., Cherry, J. D., Chang, S.-J., Knoll, M. D., Lee, M. L., Barenkamp, S., Bernstein, D., Edelman, R., Edwards, K. M. & other authors ( 2004; ). Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 190, 535–544.[CrossRef]
    [Google Scholar]
  25. McIntyre, P. B., Burgess, M. A., Egan, A., Schuerman, L. & Hoet, B. ( 2009; ). Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 27, 1062–1066.[CrossRef]
    [Google Scholar]
  26. Nasjonalt Folkehelseinstitutt ( 2007; ). Vaksinasjonsboka. http://www.fhi.no/.
  27. Nielsen, A. & Larsen, S. O. ( 1990; ). [Whooping cough epidemiology in Denmark prior to and after the introduction of whooping cough vaccination. Protective effect of the vaccine and herd immunity] (in Danish). Ugeskr Laeger 152, 597–604.
    [Google Scholar]
  28. Nielsen, A. & Rønne, T. ( 1988; ). Coverage of the childhood vaccination programme 1979–1986. EPI-NYT Uge 21, www.ssi.dk (in Danish
    [Google Scholar]
  29. Riffelmann, M., Littmann, M., Hülße, C. & Wirsing von König, C. H. ( 2008; ). Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine. Eur J Clin Microbiol Infect Dis 28, 275–279.
    [Google Scholar]
  30. Ständige Impfkommission ( 2009; ). Mitteilung der Ständigen Impfkommission am Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2009. Epidemiol Bull 30, 279–298.
    [Google Scholar]
  31. Teunis, P. F., van der Heijden, O. G., de Melker, H. E., Schellekens, J. F., Versteegh, F. G. & Kretzschmar, M. E. ( 2002; ). Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 129, 479–489.[CrossRef]
    [Google Scholar]
  32. van der Zee, A., Agterberg, C., Peeters, M., Schellekens, J. & Mooi, F. R. ( 1993; ). Polymerase chain reaction assay for pertussis: simultaneous detection and discrimination of Bordetella pertussis and Bordetella parapertussis. J Clin Microbiol 31, 2134–2140.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.020826-0
Loading
/content/journal/jmm/10.1099/jmm.0.020826-0
Loading

Data & Media loading...

Supplements

Antibody decay profiles with the IgG anti-pertussis toxin results shown on a normal scale for the -axis rather than a log scale. [PDF](205 KB)

PDF

Antibody decay profiles divided into four age groups. [PDF](169 KB)

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error